Emerging leader in renal dialysis medical device systems selects clinivation to advance multinational market access initiatives.
NATICK, MA – August 12, 2010 – Clinivation, Inc. is pleased to announce today that NxStage Medical has selected clinivation to advance certain multinational market access initiatives.
Ever-proliferating and changing global regulations generate complex challenges of execution in global market clearance operations.
Clinivation’s experienced Technology-Enabled CRO Services team understands how to approach and overcome complex development, quality, regulatory, and market access hurdles.
Unlike traditional consulting, Technology-Enabled CRO Services can employ domain-specific information technology to achieve a high operational tempo and an operational fluidity that advances to milestones and deliverables with quality and efficiency.
Quotes & Commentary:
“We look forward working with the NxStage Medical teams around the world and in the U.S., and advancing the multinational market access initiatives,” said clinivation Vice President Richard Morroney, RAC, CQA
For more information on the clinivation’s Technology-Enabled CRO Services, please visit the clinivation CRO Services homepage
For more information on the clinivation Enterprise Solution for Global Market Clearance Management, please visit the clinivation Global homepage.
For more information on the clinivation Enterprise Solution for On-Demand Global Regulatory Intelligence, please visit the clinivation WorldView homepage.
About NxStage Medical:
NxStage Medical, Inc. is a medical device company, headquartered in Lawrence, Massachusetts, USA, that develops, manufactures and markets innovative products for the treatment of End Stage Renal Disease (ESRD) and acute kidney failure.